艾滋病治疗新复方制剂绥美凯上市了

Nowadays, in the eyes of many people, AIDS is a terminal disease, and many people give up the opportunity for treatment because of misunderstandings. In fact, as long as you detect and treat early, seize the opportunity, and actively choose the life you want, you can live a normal life like normal people. AIDS requires the correct use of some antiviral drugs, otherwise AIDS will continue to attack the immune system, which will easily affect people's lives. So what about the treatment for AIDS? Is it on the market?

On January 22, 2018, GlaxoSmithKline (GSK) announced that its controlling joint venture ViiV Healthcare will be used to treat HIV The single-tablet compound preparation Triumeq (chemical name: dolutegravir), which is based on the new generation of integrase inhibitor Triumeq (chemical name: dolutegravir), is officially launched in mainland China. This drug is the only three-in-one compound drug containing dolutegravir. It is taken once a day, one tablet at a time, and has the characteristics of high efficiency, good tolerance, high resistance barrier, and few drug interactions.

This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Trimax is a medicine containing three active ingredients, used to treat HIV infection in adults and children over 12 years of age weighing more than 40 kilograms. Trimax contains three ingredients: abacavir, lamivudine and dolutegravir. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs); dolutegravir is an integrase inhibitor (INIs).

Existing research shows that one year (48 weeks) after HIV infection treatment, 93% of HIV-infected patients turned negative. Trimax should not be used on individuals who carry the HLA-B*5701 gene. Patients who carry this gene are at high risk of developing severe hypersensitivity reactions (type I allergic reactions) when using Trimax. Therefore, before taking Suimeikai, you need to complete the test to determine whether you carry the special type of "HLA-B*5701" gene. Most hospitals can't do this test now, so doctors who prescribe Suimeikai will communicate the risks with infected people. Some companies that specialize in laboratory testing can do this test. You can contact the company to do it.

Please contact your doctor immediately if the following symptoms occur during use: rash; fever; shortness of breath, sore throat, cough; nausea or vomiting, diarrhea, abdominal pain; severe tiredness or pain.

Recommended related hot articles: /newsDetail/80775.html